Hidden Liver Risks Found in Standard Blood Test

A routine heartbeat check now spots killer liver disease years before it strikes, doubling detections in silent cases and averting transplants.

Story Snapshot

Mayo Clinic’s AI-ECG model analyzes everyday EKGs to uncover advanced chronic liver disease twice as often as traditional methods.
UC San Diego’s MAPI blood score flags hidden alcohol-related liver damage using standard lab tests, outperforming rivals.
These tools target obesity, diabetes, and alcohol-driven cirrhosis that lurks without symptoms in one in three adults worldwide.
Early detection shifts care from crisis transplants to simple lifestyle fixes, slashing long-term healthcare costs.

Mayo Clinic AI-ECG Detects Silent Liver Damage

Doug Simonetto, M.D., led Mayo Clinic researchers to train an AI model on ECGs from 11,513 patients. The algorithm identifies advanced chronic liver disease signals through heart-liver connections, even in asymptomatic individuals. A randomized trial with 248 clinicians confirmed twice as many cases as standard screening. Validations used imaging and blood tests. This noninvasive approach targets cirrhosis from obesity, diabetes, hypertension, and sleep apnea.

UCSD MAPI Score Exposes Hidden Alcohol Liver Risks

Rohit Loomba, M.D., and Federica Tavaglione, M.D., Ph.D., developed the MAPI score at UC San Diego. Published February 25, 2026, in Gastroenterology, it combines standard blood labs to detect alcohol-related fatty liver when patients underreport drinking. Validated in over 500 San Diego patients and 1,800 Swedish cases, MAPI outperforms existing tests. Primary care doctors can apply it immediately to prompt further checks like PEth tests.

Rising Silent Epidemic Drives Innovation Need

Chronic liver disease strikes one in three adults globally, progressing silently from metabolic dysfunction-associated steatotic liver disease or alcohol use to fibrosis and cirrhosis. Diagnoses hit late with jaundice or bleeding, demanding transplants. Obesity and diabetes epidemics since the 1980s fuel this. Stigma hides alcohol intake. Costly biopsies limit screening. These factors demand cheap, routine tools like AI-ECG and MAPI for at-risk populations.

Stakeholders Push Noninvasive Frontiers

David Rushlow, M.D., bridged Mayo’s research to community care in the trial. Mayo Clinic funds this via its Precure initiative for predictive diagnostics. UCSD’s MASLD Research Center, backed by NIH grants, drives MAPI despite Loomba’s pharma ties, which facts support as standard for advancing care. Sonic Incytes’ FDA-approved Velacur ultrasound complements these, expanding to seniors since 2020. Hepatologists influence guidelines.

Ongoing Trials Promise Broader Impact

Mayo tracks two-year outcomes post-Nature Medicine publication. MAPI eyes large-scale primary care rollout. Johns Hopkins’ March 4, 2026, AI-liquid biopsy uses cfDNA for fibrosis signals. Short-term gains cut hospitalizations through timely meds and lifestyle changes. Long-term, lower transplant rates favor predictive over reactive medicine. Patients gain stigma-free testing; economies save versus biopsies. Communities with high MASLD prevalence, like U.S. seniors, benefit most from accessible screening.